65,437 trials
Allergy
Primary: Scores on a Scale [Net Average Combined Daily Rhinoconjunctivitis Symptom (RSS) and Medication Scores] — 0.853; 1.687 Scores on a scale — p=<0.05
Impaired Fasting Glucose · Impaired Glucose Tolerance · Vitamin D Insufficiency
Primary: Oral Glucose Insulin Sensitivity (OGIS) — -16.0; 7.8 ml/min/m^2 of body surface area — p=0.026
Depressive Disorder, Major
Primary: Change From Baseline to Week 8 in the Digit Symbol Substitution Test (DSST) — 4.60; 4.06; 2.85 Correct symbols — p=0.019
Muscle Cramps · Cirrhosis
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability (Headache) — 3 participants
Polio Immunity
Primary: Post Booster Polio Neutralizing Antibody Titers — 1715; 976; 1249; 1328 antibody titers
Fall Injury
Primary: Emergency Department and In-patient Hospitalization for Fall Injury — 5.8; 5.9; 6.1; 5.8 Fall Injury Rate per 100 person years — p=<0.05
Respiratory Failure
Primary: Percent of Participants With Successful 1st Intubation Attempt — 30; 41.67 Percent of Participants — p=0.57
Hepatitis C, Chronic
Primary: Incidence Of Sustained Virologic Response 4 Weeks (SVR4) After The Completion Of Treatment — 50; 70; 0 Percentage of participants with SVR4
Heart Valve Diseases
Primary: Atrial Fibrillation Incidence After Open Cardiac Valve Repair — 6; 13 participants
Ciliary Body and Choroid Melanoma, Medium/Large Size · Extraocular Extension Melanoma · Iris Melanoma
Primary: Objective Response Rate (CR + PR) — 7.5 percentage of participants
Colorectal Neoplasms
Primary: Progression-free Survival Rate at 9 Months (PFS-9) — 62.1; 70.2 percentage of Participants
Alcohol Dependence · Dual Diagnosis · Drug Dependence
Primary: Number of Alcohol Drinking Days in the Previous 30 (One Month Follow up) and 60 (Three Month Follow up) Days — 5.1; 6.5; 6.7; 8.8 Days Using Alcohol — p=<0.01
13-valent Pneumococcal Vaccine · Premature Birth · Immunization
Primary: Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (>=) 0.35 Microgram Per Milliliter…
Clear Cell Renal Cell Carcinoma · Recurrent Renal Cell Cancer · Stage IV Renal Cell Cancer
Primary: Overall Efficacy, Taking Into Account Both Objective Response and Meaningful Reductions in Tumor Burden That do Not Meet the RECIST Criteria for PR or CR (e.g., 5-30%…
Lymphoma
Primary: Overall Response — 3 participants